#United States #Tampa #Psilera #Scott Rairigh #neuroplastogen

Scott Rairigh Joins Psilera: A New Chapter in Healthcare Innovation

Psilera, Inc., a prominent biotechnology firm focused on pioneering therapies for intricate neurological disorders, has recently made a noteworthy addition to its executive team. Scott W. Rairigh has been appointed as the Executive Vice President of Corporate Development, a strategic role designed to bolster Psilera's business operations and commercial endeavors.

In his new position, Rairigh will be responsible for leading business development, enhancing investor relations, and shaping commercialization strategies. His expertise and leadership are expected to guide the company's advanced medicines closer to clinical adoption. Psilera's CEO, Dr. Chris Witowski, expressed enthusiastic support for Rairigh's appointment, highlighting his vigor and dedication to drug development as key factors that make him a valuable asset to the leadership team.

A Wealth of Experience

Rairigh's background is immensely impressive, boasting years of experience working with industry giants like Celgene and Bristol Myers Squibb, where he was the Global Commercial Lead for Precision Medicine initiatives in various fields including Oncology, Hematology, and Neuroscience. Before those roles, he spent 17 years at Johnson & Johnson, developing personalized medicine solutions across numerous therapeutic areas. His focus included advancing treatments for conditions that affect brain health, such as Alzheimer's disease and various mood disorders.

This diverse experience, combined with a Bachelor of Science degree from Towson University and a Master of Science from Johns Hopkins University, positions him uniquely to contribute to Psilera's mission. He also holds a Leadership Certificate from Harvard Business School, underscoring his commitment to effective management and innovative solutions in healthcare.

Commitment to Patients

In his own words, Rairigh reflects on the profound opportunity this new role presents: "This expanded role with Psilera allows me to serve patients and families more meaningfully... Their commitment to delivering first-in-class medicines that rewire and activate neuronal pathways targeting dementia, addiction, and other brain health challenges is extraordinary." His sentiment resonates with Psilera's objective to create groundbreaking therapies that reimagine the treatment landscape for neurological conditions.

Psilera is recognized for its commitment to developing revolutionary neuroplastic therapies aimed at addressing severe challenges in mental health and neurodegeneration. Its leading pipeline features promising candidates such as PSIL-006, the first of its kind targeted for treating frontotemporal dementia (FTD).

With Rairigh at the helm of corporate development, Psilera is set to navigate the complexities of the biotech landscape confidently. His dynamic leadership is anticipated to foster innovation, drive commercial success, and ultimately enhance the lives of patients grappling with challenging neurological disorders.

A venture into this new era of mindful medicine, guided by Rairigh's vision and leadership, could redefine how neurological conditions are understood and treated. Psilera remains dedicated to harnessing the potential of natural products, believing that they hold the key to transformative therapies.

To keep abreast of Psilera's advancements and this exciting new chapter with Scott Rairigh, visit www.psilera.com for more insights on their journey towards medical innovation.